On July 17, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer and advanced sarcoma, reflecting continued investigator interest in BOT+BAL across distinct disease settings and tumor types.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The NEOASIS poster will present updated data from a neoadjuvant cohort in mismatch repair-deficient (dMMR) colorectal cancer. While biologically distinct from the microsatellite-stable/mismatch repair-proficient (MSS/pMMR) population planned for ROBBIN, the study contributes to the broader clinical rationale for evaluating BOT+BAL before surgery and moving immunotherapy earlier in colon cancer.
The two additional posters will present real-world data from investigator-led studies of BOT+BAL in refractory MSS/pMMR metastatic colorectal cancer and advanced sarcoma, extending the body of independent clinical experience with the combination in heavily pretreated patients.
Presentation Details:
Abstract Title: Neoadjuvant botensilimab plus balstilimab in MMR deficient colorectal cancer: results from the NEOASIS study
Presenter: Emma Van Den Berg MD; Department of Gastrointestinal Oncology, NKI-AVL – Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Poster Presentation number: 837P
Session Title: Colon cancer
Date/Time: Sun, 25 Oct 2026; 12:00-12:45 CET | 7:00-7:45AM EST
Abstract Title: Botensilimab plus balstilimab in advanced sarcoma: real-world data from a Spanish expanded access program
Presenter: Carlos López-Jiménez MD, PhD; Fundación Jiménez Díaz University Hospital, Madrid, Spain
Poster Presentation number: 3771P
Session Title: Sarcoma
Date/Time: Mon, 26 Oct 2026: 12:00-12:45 CET | 7:00-7:45AM EST
Abstract Title: Botensilimab and balstilimab in refractory pMMR/MSS metastatic colorectal cancer: real-world data from a multicenter AGEO study
Presenter: Louis Piton, MD, Paris-Cité University, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France
ePoster Abstract number: 905eP
Session Title: Colon cancer
(Press release, Agenus, JUL 17, 2026, View Source [SID1234669289])